Cost‐utility analysis of normothermic machine perfusion compared to static cold storage in liver transplantation in the Canadian setting

To estimate the incremental cost‐effectiveness of a liver transplant program that utilizes normothermic machine perfusion (NMP) alongside static cold storage (SCS) compared to SCS alone (control). A Markov model compared strategies (NMP vs. control) using 1‐year cycle lengths over a 5‐year time horizon from the public healthcare payer perspective. Primary micro‐costing data from a single center retrospective trial were applied along with utility values from literature sources. Transition probabilities were deduced using the retrospective trial cohort, local transplant data, and supplemented with literature values. Scenario and probabilistic sensitivity analysis (PSA) were conducted. The NMP strategy was cost‐effective in comparison to the control strategy, which was dominated. The mean cost for NMP was $456 455 (2021 US$) and the control was $519 222. The NMP strategy had greater incremental quality‐adjusted life years (QALYs) gains over 5 years compared to the control, with 3.48 versus 3.17, respectively. The overarching results remained unchanged in scenario analysis. In PSA, NMP was cost‐effective in 63% of iterations at a willingness‐to‐pay threshold of $40 941. The addition of NMP to a liver transplant program results in greater QALY gains and is cost‐effective from the public healthcare payer perspective. In liver transplantation, a cost‐utility analysis comparing utilization of static cold storage alone versus normothermic machine perfusion in addition to static cold storage shows that the addition of normothermic machine perfusion to be cost‐effective for the health care system.